At a glance
ClinicalIndex Comparison RecordN/ACompleted· 2,580 enrolled
Drug / intervention
Bimatoprostdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
In Brief
An observational study evaluating Bimatoprost for Glaucoma, Open-Angle and Ocular Hypertension. Completed, enrolled 2,580 participants across 2 sites in 2 countries.
Detailed Summary
An observational study comparing changing from an IOP-lowering treatment to a bimatoprost-containing IOP treatment in primary open-angle glaucoma (POAG) or ocular hypertension (OHT). Visits and treatment are per normal clinical practice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Open-Angle, Ocular Hypertension
CountriesGermany, Netherlands
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2012
First PostedJul 2012
Primary CompletionApr 2013
TodayJul 2026
First PostedJul 20, 2012
Enrollment StartMay 1, 2012
Primary CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 14.0 years ago
Interventions
Bimatoprostdrug
Bimatoprost-containing eye drops administered in the affected eye(s) at a dose determined by the physician in accordance with standard of care for up to 12 weeks.